CGC Fundamental Analysis - CANOPY GROWTH CORP

Fundamental Rating

Overall CGC gets a fundamental rating of 2 out of 10. We evaluated CGC against 191 industry peers in the Pharmaceuticals industry. While CGC seems to be doing ok healthwise, there are quite some concerns on its profitability. CGC does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CGC has reported negative net income.

In the past year CGC has reported a negative cash flow from operations.

CGC had negative earnings in each of the past 5 years.

CGC had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -36.07%, CGC perfoms like the industry average, outperforming 46.35% of the companies in the same industry.

CGC's Return On Equity of -52.42% is in line compared to the rest of the industry. CGC outperforms 52.60% of its industry peers.

		Industry Rank	Sector Rank
ROA	-36.07%
ROE	-52.42%
ROIC	N/A

ROA(3y)-83.37%

ROA(5y)-56.25%

ROE(3y)-219.63%

ROE(5y)-143.17%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CGC's Gross Margin of 27.49% is in line compared to the rest of the industry. CGC outperforms 55.21% of its industry peers.

The Profit Margin and Operating Margin are not available for CGC so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	27.49%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CGC does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for CGC has been increased compared to 1 year ago.

The number of shares outstanding for CGC has been reduced compared to 5 years ago.

Compared to 1 year ago, CGC has an improved debt to assets ratio.

2.2 Solvency

CGC has an Altman-Z score of -9.38. This is a bad value and indicates that CGC is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -9.38, CGC is not doing good in the industry: 69.79% of the companies in the same industry are doing better.

CGC has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.

CGC has a Debt to Equity ratio of 0.33. This is comparable to the rest of the industry: CGC outperforms 41.15% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.33
Debt/FCF	N/A
Altman-Z	-9.38

ROIC/WACCN/A

WACC11.76%

2.3 Liquidity

CGC has a Current Ratio of 5.50. This indicates that CGC is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 5.50, CGC is in the better half of the industry, outperforming 65.10% of the companies in the same industry.

CGC has a Quick Ratio of 4.23. This indicates that CGC is financially healthy and has no problem in meeting its short term obligations.

CGC has a Quick ratio of 4.23. This is in the better half of the industry: CGC outperforms 62.50% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.5
Quick Ratio	4.23

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.25%, which is quite impressive.

CGC shows a decrease in Revenue. In the last year, the revenue decreased by -0.67%.

CGC shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.57% yearly.

EPS 1Y (TTM)58.25%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.32%

Revenue 1Y (TTM)-0.67%

Revenue growth 3Y-19.22%

Revenue growth 5Y-7.57%

Sales Q2Q%5.86%

3.2 Future

Based on estimates for the next years, CGC will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.29% on average per year.

CGC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.39% yearly.

EPS Next Y94.86%

EPS Next 2Y40.65%

EPS Next 3Y25.5%

EPS Next 5Y15.29%

Revenue Next Year2.14%

Revenue Next 2Y4.71%

Revenue Next 3Y30.84%

Revenue Next 5Y5.39%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGC. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

CGC's earnings are expected to grow with 25.50% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y40.65%

EPS Next 3Y25.5%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CGC!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

CANOPY GROWTH CORP

NASDAQ:CGC (12/26/2025, 8:00:00 PM)

After market: 1.2 +0.01 (+0.84%)

1.19

-0.12 (-9.16%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-07 2025-11-07/bmo

Earnings (Next)02-05 2026-02-05/bmo

Inst Owners10.93%

Inst Owner Change91.21%

Ins Owners0.18%

Ins Owner Change5.67%

Market Cap438.47M

Revenue(TTM)278.61M

Net Income(TTM)-385.85M

Analysts47.69

Price Target2.81 (136.13%)

Short Float %10.18%

Short Ratio1.33

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)51.01%

Min EPS beat(2)8.22%

Max EPS beat(2)93.8%

EPS beat(4)2

Avg EPS beat(4)-51.44%

Min EPS beat(4)-206.63%

Max EPS beat(4)93.8%

EPS beat(8)2

Avg EPS beat(8)-152.68%

EPS beat(12)3

Avg EPS beat(12)-166.46%

EPS beat(16)4

Avg EPS beat(16)-163.73%

Revenue beat(2)1

Avg Revenue beat(2)0.9%

Min Revenue beat(2)-7.76%

Max Revenue beat(2)9.57%

Revenue beat(4)3

Avg Revenue beat(4)3.88%

Min Revenue beat(4)-7.76%

Max Revenue beat(4)9.57%

Revenue beat(8)5

Avg Revenue beat(8)2.85%

Revenue beat(12)6

Avg Revenue beat(12)1.1%

Revenue beat(16)8

Avg Revenue beat(16)-0.85%

PT rev (1m)5.15%

PT rev (3m)2.92%

EPS NQ rev (1m)0%

EPS NQ rev (3m)70.39%

EPS NY rev (1m)54.94%

EPS NY rev (3m)58.18%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-8.94%

Revenue NY rev (1m)-5.7%

Revenue NY rev (3m)-5.7%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2.15
P/FCF	N/A
P/OCF	N/A
P/B	0.82
P/tB	0.99
EV/EBITDA	N/A

EPS(TTM)-2.05

EYN/A

EPS(NY)-0.09

Fwd EYN/A

FCF(TTM)-0.19

FCFYN/A

OCF(TTM)-0.18

OCFYN/A

SpS0.55

BVpS1.46

TBVpS1.2

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-36.07%
ROE	-52.42%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	27.49%
FCFM	N/A

ROA(3y)-83.37%

ROA(5y)-56.25%

ROE(3y)-219.63%

ROE(5y)-143.17%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	0.33
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	18.94%
Cap/Sales	2.77%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.5
Quick Ratio	4.23
Altman-Z	-9.38

F-Score5

WACC11.76%

ROIC/WACCN/A

Cap/Depr(3y)15.39%

Cap/Depr(5y)45.04%

Cap/Sales(3y)2.72%

Cap/Sales(5y)9.89%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)58.25%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.32%

EPS Next Y94.86%

EPS Next 2Y40.65%

EPS Next 3Y25.5%

EPS Next 5Y15.29%

Revenue 1Y (TTM)-0.67%

Revenue growth 3Y-19.22%

Revenue growth 5Y-7.57%

Sales Q2Q%5.86%

Revenue Next Year2.14%

Revenue Next 2Y4.71%

Revenue Next 3Y30.84%

Revenue Next 5Y5.39%

EBIT growth 1Y51.22%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year89.39%

EBIT Next 3Y31%

EBIT Next 5Y19.3%

FCF growth 1Y81.5%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y82.69%

OCF growth 3YN/A

OCF growth 5YN/A

CANOPY GROWTH CORP / CGC FAQ

Can you provide the ChartMill fundamental rating for CANOPY GROWTH CORP?

ChartMill assigns a fundamental rating of 2 / 10 to CGC.

Can you provide the valuation status for CANOPY GROWTH CORP?

ChartMill assigns a valuation rating of 1 / 10 to CANOPY GROWTH CORP (CGC). This can be considered as Overvalued.

How profitable is CANOPY GROWTH CORP (CGC) stock?

CANOPY GROWTH CORP (CGC) has a profitability rating of 1 / 10.

What is the financial health of CANOPY GROWTH CORP (CGC) stock?

The financial health rating of CANOPY GROWTH CORP (CGC) is 4 / 10.

CANOPY GROWTH CORP (CGC) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

CANOPY GROWTH CORP / CGC FAQ

Can you provide the ChartMill fundamental rating for CANOPY GROWTH CORP?

Can you provide the valuation status for CANOPY GROWTH CORP?

How profitable is CANOPY GROWTH CORP (CGC) stock?

What is the financial health of CANOPY GROWTH CORP (CGC) stock?